Body Pharm GHK-Cu 50 Pen

The Body Pharm GHK-Cu 50 pen is a pre-filled research peptide device containing 50 mg of GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) in stable solution, available through JCSG.org with cold-chain delivery across South Africa. The current price is shown in the buy box.

Attribute	Detail
Peptide	GHK-Cu (glycyl-L-histidyl-L-lysine copper complex)
Total content per pen	50 mg
Format	Pre-filled, dose-marked pen
Brand	Body Pharm
Stated dose per marker	1 mg per dose marker (see product page for full specification)
Positioning	Research peptide; for research use only

GHK-Cu is a naturally occurring tripeptide first isolated from human plasma and described by Loren Pickart in the early 1970s. The copper complex form is the variant studied in dermatology and cosmetic science literature. In vitro and animal-model work has examined its role in collagen synthesis, angiogenesis, and wound healing pathways because the Cu²⁺-bound complex shows measurable activity in fibroblast assays and tissue models.

The pre-filled pen format means the solution arrives sealed in a dose-marked cartridge — no reconstitution required. For broader context, see the GHK-Cu peptide overview and related tissue-repair research on BPC-157.

Key Takeaways

• Pre-filled 50 mg GHK-Cu pen — no reconstitution, ready to use
• Dose-marked calibration reduces handling variability versus lyophilised vials
• GHK-Cu is not SAHPRA-registered as a medicine; pens are sold as research products
• Cold-chain storage at 2–8 °C essential; JCSG ships with appropriate cold-chain packaging

GHK-Cu Research Background: What the Science Shows

As of 2026, the peptide's reputation rests on pre-2020 cosmetic and wound-healing trials, in vitro work, and animal models. No large-scale peer-reviewed human randomised controlled trials (RCTs) have confirmed dermatological or hair-growth efficacy for injected GHK-Cu. Researchers evaluating GHK-Cu for a protocol should treat the absence of large-scale human injection data as a significant limitation.

The molecule is a tripeptide (glycyl-L-histidyl-L-lysine) with high affinity for copper(II) ions. The histidine residue contains an imidazole ring that coordinates strongly with Cu²⁺. That copper-binding step is what most pre-clinical literature treats as the active form, since the Cu²⁺-bound complex is the variant studied in collagen and antioxidant signalling assays. Loren Pickart first isolated GHK from human plasma in the early 1970s, and his later work characterised the copper complex used in cosmetic formulations.

Research pathways most commonly cited

Five mechanistic pathways dominate the GHK-Cu literature:

• Collagen production and elastin synthesis — in vitro fibroblast assays have measured upregulation of extracellular matrix proteins after GHK-Cu exposure, feeding into skin regeneration and elasticity research.
• Angiogenesis — animal-model wound studies have reported increased capillary formation in GHK-Cu-treated tissue.
• Wound healing — legacy human topical trials, mostly pre-2020, examined wound closure rates with GHK-Cu-containing dressings and creams.
• Follicular signalling for hair growth support — in vitro work has examined GHK-Cu's interaction with inflammatory cytokines in dermal papilla and keratinocyte models.
• Antioxidant signalling — assays measuring reactive oxygen species in skin cell models show reduced oxidative stress markers because the copper centre catalyses superoxide dismutase-like activity.

None of these pathways translate automatically to outcomes from a pre-filled injectable pen. The delivery route (subcutaneous vs. topical), dose, and copper:peptide ratio in current South African pens have not been independently characterised in published human trials.

For researchers cross-referencing tissue-repair peptides, BPC-157 sits in a similar evidence category: substantial pre-clinical data, limited controlled human evidence as of 2026.

Body Pharm GHK-Cu 50 Pen: Full Specifications

The Body Pharm GHK-Cu 50 pen contains 50 mg of GHK-Cu in a pre-filled stable solution format. The table below consolidates verified product specifications.

Specification	Detail
Total peptide content	50 mg GHK-Cu per pen
Format	Pre-filled stable solution pen, ready to use
Doses per pen	50 doses × 1 mg per dose marker
Injection volume per dose	See product page
Price	See buy box
Certificate of Analysis (CoA)	Request from JCSG at point of purchase
Manufacturer entity	Body Pharm

Sourcing and Fulfilment in South Africa

The Body Pharm GHK-Cu 50 pen is available through JCSG.org in South Africa, with:

• Cold-chain fulfilment — pens are dispatched with insulated packaging and gel packs to maintain the 2–8 °C cold chain across all South African provinces
• Authentic Body Pharm stock — sourced directly, not through grey-market resellers
• CoA availability — request a batch Certificate of Analysis at checkout
• Nationwide delivery — Gauteng, KZN, Western Cape, Northern Cape, and beyond

SAHPRA Classification: What "Research Chemical" Means in SA

GHK-Cu peptide pens are sold in South Africa under a "research purposes only" designation because SAHPRA has not assessed or approved them for human therapeutic use. They sit outside the registered medicines framework as of 2026. The "research chemical" label is commercial positioning, not a SAHPRA category.

SAHPRA (South African Health Products Regulatory Authority) administers the Medicines and Related Substances Act 101 of 1965 (as amended). This Act classifies registered medicines into Schedules 0 through 7 based on risk, dependence potential, and prescribing controls. GHK-Cu does not appear by name in SAHPRA's published schedules as of 2026. It is not individually scheduled and is generally treated as a cosmetic ingredient (in topical formats) or an unregistered product (in injectable pen format). No peptide-pen-specific SAHPRA guidance or enforcement notice was located for the 2023–2026 period.

SAHPRA status summary

Aspect	Status for GHK-Cu pens in SA (2026)
SAHPRA-registered medicine	No
Listed in Schedules 0–7 by name	No
Approved for human therapeutic use	No
Subject to peptide-pen-specific SAHPRA notice	None located
Sold with therapeutic claims	Would trigger general unregistered-medicine provisions

A product runs into trouble under the Act when it is marketed with therapeutic claims without registration, or when it contains a scheduled active supplied outside scheduling controls. SAHPRA's enforcement powers rest on the Medicines Act's Schedule definitions and the prohibition on unregistered medicines making therapeutic claims. GHK-Cu itself meets neither condition. The pen format and injectable route place it in a grey zone that SAHPRA could reassess at any point.

Compliance note: This section reflects publicly accessible regulatory information as of November 2026 and does not constitute legal advice. Scheduling positions change. Verify current SAHPRA status directly before purchase. The GHK-Cu peptide overview and BPC-157 research peptide pages cover adjacent regulatory context on research peptides studied in tissue-repair work.

For research use only. Not for human consumption.

Storage and Handling for Pre-Filled GHK-Cu Pens

Pre-filled GHK-Cu pens require refrigerated cold-chain storage at 2–8 °C, protection from light, and must not be frozen. Peptide solutions aggregate and lose potency at sub-zero temperatures. The in-use window is typically capped at 28 days once the first dose is drawn, and bacterial contamination risk rises after the cartridge seal is broken.

Parameter	General peptide pen standard
Unopened storage	2–8 °C, refrigerated, light-protected
In-use window	Up to 28 days refrigerated
Freezing	Do not freeze (peptide aggregation risk)
Transport	Cold-chain packaging with gel packs
Pre-use check	Clear solution, no particulates, in-date

Why the South African climate matters

Summer ambient temperatures in Gauteng, KZN, and the Northern Cape regularly push past 35 °C — well above the 2–8 °C cold-chain band. That gap accelerates peptide degradation because heat increases molecular motion and hydrolysis rates. JCSG dispatches all GHK-Cu pens in insulated cooler packaging with gel packs as standard. Requesting a morning delivery slot helps minimise transit exposure.

Pre-use checks

Before priming the pen, inspect the cartridge for a clear, colourless-to-pale-blue solution. GHK-Cu carries a faint copper tint because of the Cu²⁺ complex. Check the printed expiry and confirm the pen has remained refrigerated since arrival. Discard if cloudy, discoloured beyond the expected pale blue, or if the cold chain was broken in transit. The GHK-Cu peptide overview covers stability factors in more depth.

Pen Format vs. Vial: Why Format Matters for Research Use

The pen format trades flexibility for consistency. A pre-filled, pre-dissolved stable solution pen removes the reconstitution step, which is the largest source of variability in vial-based peptide research. For researchers tracking dose-response across a series, that matters more than the per-mg cost saving a vial typically offers.

The Body Pharm GHK-Cu 50 pen ships as a stable solution requiring no bacteriostatic water, no swirling, and no syringe transfer. Lyophilised vials, by contrast, require the researcher to calculate reconstitution volume, draw bacteriostatic water, mix without shearing the peptide, and store the resulting solution under the same 2–8 °C cold-chain conditions discussed earlier.

Factor	Pre-filled pen (Body Pharm GHK-Cu 50)	Lyophilised vial (generic GHK-Cu)
Reconstitution	Not required, ships as solution	Required, bacteriostatic water sourced separately
Dose calibration	Dial-marked, 1 mg per marker	Manual syringe measurement
Dose flexibility	Fixed to marker increments	Adjustable to any volume
Handling error risk	Lower, fewer transfer steps	Higher, multiple transfer steps
Cost per mg	See buy box	Typically lower
Portability	Self-contained, refrigerated transport only	Powder stable at ambient until reconstituted

Pens suit researchers who prioritise repeatable dosing across a protocol because the dial-marked increments reduce measurement variability. Vials suit those running variable-dose comparisons or pairing GHK-Cu with adjacent peptides such as BPC-157, where custom volumes matter. The GHK-Cu peptide overview covers format-agnostic stability factors in more detail.

Related Peptide Pens for Regenerative Research

Researchers comparing the Body Pharm GHK-Cu pen often cross-reference adjacent peptides studied in tissue-repair, mitochondrial, and cellular-energy pathways. These compounds share mechanistic overlap in fibroblast activation and growth-factor signalling. The peptides most commonly co-investigated on JCSG South Africa are summarised below for research context only.

BPC-157

A 15-amino-acid pentadecapeptide derived from gastric juice, investigated in pre-clinical models of tendon, ligament, and gastrointestinal repair. Animal studies show accelerated healing timelines and reduced inflammatory markers. See the BPC-157 research peptide page for the SA listing and methodology notes.

TB-500

A synthetic fragment of thymosin beta-4, frequently paired with BPC-157 in tissue-repair literature. Its role in actin regulation and cell migration research is well documented, with studies showing it modulates inflammation and promotes angiogenesis in wound models.

MOTS-C

A mitochondrial-derived peptide studied in metabolic and cellular-energy contexts. It activates AMPK signalling and improves mitochondrial function in pre-clinical models. The mechanism is distinct from GHK-Cu's copper-binding pathway, but the two overlap in cellular-repair research themes.

Browse all peptides available in South Africa

Frequently Asked Questions

Question	Short Answer
Legal to buy in SA?	Not individually scheduled by SAHPRA; sold as research material
Doses per 50 mg pen?	50 doses × 1 mg per marker (see product page)
Storage?	Refrigerated 2–8 °C
SAHPRA approved?	No GHK-Cu product is SAHPRA-registered as a medicine
Where to buy?	Available on JCSG.org — see buy box for price